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Abstract
Increased versican expression in breast tumors is predictive of relapse and has negative impact on survival rates. The C-
terminal G3 domain of versican influences local and systemic tumor invasiveness in pre-clinical murine models. However,
the mechanism(s) by which G3 influences breast tumor growth and metastasis is not well characterized. Here we evaluated
the expression of versican in mouse mammary tumor cell lines observing that 4T1 cells expressed highest levels while 66c14
cells expressed low levels. We exogenously expressed a G3 construct in 66c14 cells and analyzed its effects on cell
proliferation, migration, cell cycle progression, and EGFR signaling. Experiments in a syngeneic orthotopic animal model
demonstrated that G3 promoted tumor growth and systemic metastasis in vivo. Activation of pERK correlated with high
levels of G3 expression. In vitro, G3 enhanced breast cancer cell proliferation and migration by up-regulating EGFR signaling,
and enhanced cell motility through chemotactic mechanisms to bone stromal cells, which was prevented by inhibitor AG
1478. G3 expressing cells demonstrated increased CDK2 and GSK-3b (S9P) expression, which were related to cell growth.
The activity of G3 on mouse mammary tumor cell growth, migration and its effect on spontaneous metastasis to bone in an
orthotopic model was modulated by up-regulating the EGFR-mediated signaling pathway. Taken together, EGFR-signaling
appears to be an important pathway in versican G3-mediated breast cancer tumor invasiveness and metastasis.
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Introduction
Versican is a member of the large aggregating chondroitin
sulfate proteoglycans and is a member of the lecticans family [1].
To date, the entire primary structures of human [2], murine [3],
bovine [4], and chick [5], versican coding mRNAs have been
sequenced. Structurally all versican spliced forms include an N-
terminal G1 domain, a glycosamingoglycan (GAG) attachment
region, and a C-terminus containing a selectin-like (G3) domain
[1],[6]. The G3 domain contains two epidermal growth factor
(EGF)-like repeats, a lectin-like motif (carbohydrate recognition
domain or CRD), and a complement binding protein (CBP)-motif.
Versican interacts with its binding partners through its N- and C-
terminal globular regions as well as its central GAG-binding
region [7],[8]. By now four isoforms of versican (V0, V1, V2, V3)
have been identified in various tissues [2]. The expression levels of
versican V1 are high in the embryonic brain, wheras V2 is the
dominant isoform with the mature central nervous system [4]. It is
known to associate with a number of molecules in the extracellular
matrix (ECM) including hyaluronan [9] tenascin-R [10], fibulin-1
and -2 [11] fibrillin-1 [12], fibronectin [13], P- and L-selectin, and
chemokines [8]. Versican also binds to the cell surface proteins
epidermal growth factor receptor (EGFR) [8], CD44 [14], integrin
b1 [15], and P-selectin glycoprotein ligand-1 [14]. As a result,
versican influences the regulation of cell motility, growth, and
differentiation [16],[17],[18].
Given their ubiquitousness and high degree of conservation, it is
likely that G1 and G3 play vital roles in proteoglycan function.
The G1 domain has been shown to inhibit the attachment of
glycosaminoglycan chains and the secretion of the products from
the cell, while the G3 domain appears to enhance both processes
[19]. There is increasing recognition of the importance of versican
G1 to tumor growth, motility, and metastasis [20],[21]. Versican
exerts its effect on astrocytoma cell migration and adhesion
through the G1 domain [20]. In astrocytoma and chondrocyte
morphogenesis, the effects of versican are greatly reduced when
the G3 domain or EGF-like motifs within the G3 domain were
deleted [22],[23]. Actually the terminal domains of versican may
differentially control propagation of tumor cells and diversely
modulate their responses to environmental hyaluronan [21].
Versican expression is enhanced during wound repair and tumor
growth. In human tumors, versican is detected in the interstitial
tissues at the invasive margins of breast carcinoma and in the elastic
tissues associated with tumor invasion [22],[24],[25]. Immunolo-
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carcinoma, has been reported [26]. The high expression of versican
in human breast tumors appears prognostic, being predictive of
relapse, and negatively impacting overall survival rates [27],[28].
The mechanism(s) by which versican facilitates tumor growth and
metastatic transformation in breast cancer is not well characterized.
The phenotype of metastatic human breast cancer includes a
predilection for spread to bony sites [29].
The EGF receptor is a transmembrane tyrosine kinase that is
activated by tyrosine autophosphorylation after ligand-induced
dimerization [30]. The Ras-Raf pathway leading to the activation
of extracellular regulated protein kinases (ERKs) has been the
subject of intense interest because of its role in the regulation of
proliferation, differentiation, and cell–matrix interactions [31].
ERK1 and ERK2 are dually phosphorylated on threonine and
tyrosine by the upstream MAP kinase, MEK. ERKs then
phosphorylate and activate a variety of substrates including
transcription factors, protein kinases and phosphotyrosine protein
phosphatases leading to positive or negative regulation of signaling
cascades [32].
Over-expression of EGF and its receptor (EGFR) has been
found in many human tumors and cell lines, including breast
cancer [33],[34]. With many other interactions occurring, the
typical EGFR–MEK–ERK is believed to be a key element of a
complex signaling network involved in survival signaling, cell
migration, metastasis, and angiogenesis [35],[36]. Different
approaches and targets are under evaluation and development
for the therapeutic intervention of this key signal pathway in breast
cancer [32],[37].
In the current study, we have investigated the mechanisms of
versican G3 domain effects on mouse mammary tumor cell
growth, migration, and proliferation. We also evaluated its effect
on spontaneous metastasis to bone in an orthotopic model with
focus on EGFR-mediated signaling. In order to investigate the
effect of versican G3 on breast cancer cell growth and metastasis,
we first characterized the expression of versican in murine
mammary epithelial tumor cell lines 67NR, 66c14, 4T07, and
4T1, which were derived from a single spontaneous arising
mammary tumor from Balb/cfC3H mice [38]. The tumorigenic
and metastatic characteristics of these cells have been examined in
detail [39],[40]. Although they share a common origin, these lines
are phenotypically heterogeneous in their metastatic behavior.
4T1 cell line is one of the very few lines of any origin that
spontaneously metastasizes to bone, closely mimicing Stage IV
human breast cancer, which hematogeneously metastasizes to the
lung, liver, bone, and brain via the hematogenous route, whereas
66c14 metastasizes to the lung and liver via the lymphatics [41].
67NR cells fail to leave the primary site, while 4T07 cells are
highly tumorigenic but fail to metastasize [39]. To evaluate the
potential influence of versican G3 on EGFR signally, we
exogenously expressed the versican G3 protein in a cell line with
low basal versican, pEGFR, and pERK expression. Then we
utilized a syngeneic orthotopic model of spontaneous breast cancer
metastasis to test whether the exogenous expression of the versican
G3 fragment in a mammary carcinoma 66cl4 cell line (a cell line
that normally metastasizes to the lung but not to bone) was
sufficient not only to promote local tumor growth but also to
enhance metastasis to bone from the mammary fat pad.
Materials and Methods
Material Supplies
The monoclonal antibodies against ERK2, pERK, fibronectin, and
CDK2, and the polyclonal antibodies against EGFR, pEGFR, cyclin
A, cyclin B, cyclin D, cyclin E, and CDK6 were obtained from Santa
Cruz Biotechnology. EGF, selective EGFR inhibitor AG 1478,
selective MEK inhibitor PD 98059, hydroxyurea, and the monoclonal
antibody against b-actin used in the study were obtained from Sigma.
The polyclonal antibodies against versican V1 isoform, Glycogen
synthase kinase-3b serine-9 phosphorylation (GSK-3b,S 9 P ) ,a n d
monoclonal antibody against vimentin were obtained from Abcam.
The monoclonal antibodies against GSK-3b, N-cadherin, E-cadherin
were obtained from BD Transduction Laboratories. Horseradish
peroxidase-conjugated goat anti-mouse IgG and horseradish peroxi-
dase-conjugated goat anti-rabbit IgG were obtained from Bio-Rad.
Immunoblotting was performed using the ECL Western blot detection
kit. Cell Proliferation Reagent WST-1, and High Pure PCR Template
Preparation kits were obtained from Roche Applied Science.
Versican expression in mammary tumor cell lines
Mouse mammary tumor cell lines 67NR, 66c14, 4T07, 4T1
were cultured in Dulbecco’s Modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum, penicillin (100 U/ml) and
streptomycin (100 mg/ml) and maintained at 37uC in a humidified
atmosphere of 5% CO2. Basal expression of versican amongst the
four cell lines was compared by immunoblotting.
Exogenous expression of versican G3 in breast cancer cell
lines
The pcDNA1 - G3 construct and pcDNA1 - G3 fragment
lacking the EGF-like motifs (G3DEGF) construct were generated
by us [22],[23]. Mouse mammary tumor cell lines 66c14, 4T07,
4T1 and human breast cancer cell line MT-1 were transfected
with pcDNA1-vecor and G3 constructs. Three days after
transfection, Geneticin was added to the growth medium at a
concentration of 1 mg/ml, and the cells were maintained in this
medium until individual colonies were large enough for cloning.
Chemically selected stable cell lines were maintained in medium
containing 0.5 mg/ml Geneticin or stored in liquid nitrogen. The
66c14 cells were transiently transfected with G3 construct,
G3DEGF construct, or the control vector. A leading sequence
was engineered to both construct by us previously [19]. This
leading peptide was obtained from link protein, which contains
180 nucleotides producing 60 amino acids. We have been using
the system for many years and found that it is a powerful leading
peptide for protein secretion. In addition, it contains an epitope
recognized by the monoclonal antibody 4B6 [42].
Cell attachment assays
Based upon experimental data demonstrating low basal expres-
sion of versican in 66c14 cells, a versican G3 construct was stably
expressed in 66c14 cells using established techniques [22],[43]. The
expression of versican G3 construct in the cell lysate and culture
medium was examined with monoclonal antibody 4B6. Subse-
quently 2610
5 66c14 cells transfected with versican G3 or control
vector were seeded onto 6-well culture dishes in DMEM medium
with varying amounts of FBS (2.5, 5, and 10%) for 3 h. Cell
attachment assays were performed [19],[23]. Adherent cells were
fixed, and the cell numbers were counted in randomly selected high
power fields under an inverted light microscope. In selected
experiments, cell suspensions were cultured with EGF (20 ng/ml),
EGFR inhibitor AG 1478 (0.2, 2.0, and 5.0 mM), and selective
MEK inhibitor PD 98059 (20 mM, 50 mM, 100 mM).
Cell proliferation assays
Versican G3- and vector-transfected 66c14 cells (2610
4 cells)
were seeded onto 6-well dishes in 10% FBS/DMEM medium and
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culture medium was removed and the cultures were washed with
PBS, followed by culturing in DMEM with differing FBS
concentrations (2.5, 5, and 10%). Cells were harvested daily and
cell number was analyzed by coulter counter. Cell proliferation
assays were also performed with colorimetric proliferation assay
(Cell Proliferation Reagent WST-1). Versican G3 and control
vector transfected 66c14 (2610
3 cells/well) cells were cultured in
100 ml FBS/DMEM medium in 96 wells tissue culture micro-
plates. The absorbance of the samples against a background blank
control was measured daily for 5 days by a microplate (ELISA)
reader. In selected experiments, cell suspensions were cultured
with EGF (20 ng/ml), EGFR inhibitor AG 1478 (0.2, 2.0, and
5.0 mM), and selective MEK inhibitor PD 98059 (20, 50, and
100 mM).
Cell migration assays
(A) Wound-healing assay. Versican G3- and vector-
transfected 66c14 cells (2610
5) were seeded onto 6-well dishes in
10% FBS/DMEM medium and maintained at 37uC until they
reached 95% confluence. The monolayer G3- and vector-
transfected cells were wounded by a sterile pipette tip to create a
1-mm cell-free path. Culture medium was removed and the
samples were washed with PBS, followed by culturing in 10%
FBS/DMEM medium with 2 mM of the cell growth suppressor
hydroxyurea. Cells were fixed in 3.7% paraformaldehyde at the
indicated time intervals (every 24 hours) and photographed under
a low-magnification microscope. As well, the wounded cultures
were incubated with medium containing 2.0 mM EGFR inhibitor
AG 1478 or 50 mM selective MEK inhibitor PD 98059, followed
by photography. The distances between the wounding centre and
the front of the migrating cells (vertical axis) were measured for
statistical analysis.
(B) Modified chemotactic Boyden chamber motility
assays. This assay was performed using 24-well cell culture
plates and a 3 mm cell culture insert. The tibias and femora were
harvested from Balb/c mice, crushed and digested with a solution
of DMEM containing collagenase type II (6 mg/ml) and dispase II
(8 mg/ml) for 60 minutes. The cell suspension was filtered through
a7 0mm nylon filter and washed three times by centrifugation in
DMEM. The cell pellet was resuspended in DMEM, 10% FBS
and maintained at 37uC overnight. After 12–16 h of culture, these
cells were allowed to form a confluent monolayer in the bottom
well of Transwell migration chambers. The medium was removed
and the cultures were washed with PBS, followed by culturing in
600 ml 10% DMEM with or without 2.0 mM AG 1478, 50 mMP D
98059 at 37uC for an additional incubation of 2 hours. The G3-
transfected 66c14 cells (1610
5 cells in 100 ml serum free DMEM
medium with or without 2.0 mM AG 1478, 50 mM PD 98059)
were gently injected into each filter insert (upper chamber) and
then incubated at 37uC for 4 h. The filter inserts were removed
from the chambers, fixed with methanol for 5 minutes, and stained
with Harris’ Haemotoxylin for 20 minutes. Samples were
subsequently washed, dried, and mounted onto slides for analysis
using a light microscope at 32 times magnification. Migrating cells
were stained blue. Migration experiments were performed in
triplicate and were counted in three fields of views/membrane.
Western blot analysis
Protein samples were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on separating gel
containing 7–10% acrylamide. Separated proteins were trans-
blotted onto a nitrocellulose membrane in 16Tris/glycine buffer
containing 20% methanol at 60 V for 2 hours in a cold room. The
membrane was blocked in TBST (10 mM Tris-Cl, pH 8.0,
150 mM NaCl, 0.05% Tween 20) containing 5% non-fat dry milk
powder (TBSTM) for 1 hour at room temperature, and then
incubated with primary antibodies at 4uC overnight. The
membranes were washed with TBST (3630 minutes) and then
incubated with appropriate horseradish peroxidase-conjugated
secondary antibodies in TBSTM for 1 hour. After washing as
above, the bound antibodies were visualized with an ECL
detection kit as described previously [44].
Cell cycle analysis
The expression of cell cycle-related proteins was analyzed by
immumoblotting probed with appropriate antibodies as described
above. The G3- and vector-transfected 66c14 cells were cultured
in 10% FBS/DMEM media at 37uC, 5% CO2 with or without
EGFR inhibitor AG 1478 (0.2, 2.0, and 5.0 mM), selective MEK
inhibitor PD 98059 (20, 50, and 100 mM). The cells were washed
and resuspended in cold PBS and incubated in ice-cold 70%
ethanol for 3 hours. The cells were then centrifuged at 1,500 rpm
for 10 minutes and resuspended in propidium iodide (PI) master
mix (40 mg/ml PI and 100 mg/ml RNase in PBS) at a density of
56105/ml and incubated at 37uC for 30 minutes before analysis
with flow cytometry. Cell cycle related proteins cyclin A, cyclin B,
cyclin D, cyclin E, CDK2, CDK6 and GSK-3b were analyzed by
immunoblotting.
In vivo tumorigenicity in balb/c mice, local tumor growth
and metastasis
The G3- and vector-transfected 66c14 cells were cultured in
10% FBS/DMEM media at 37uC with 5% CO2. At 70% to 80%
subconfluency, the cells were given fresh 10% FBS/DMEM media
24 hours before inoculation into the mice. Cell viability was
determined by trypan blue exclusion, and cells were suspended
with greater than 95% viability without cell clumping. Following
appropriate institutional animal care committee approval, four-
week-old Balb/c mice were injected transdermally with the G3-
and vector-transfected 66c14 cells (1610
7 cells in 150 ml 10%
FBS/DMEM medium) into the fourth (inguinal) mammary fat pad
using a 1 ml syringe with a 26 G needle. Each group had 4 mice,
which were chosen at random. Tumors were measured weekly
thereafter. Four weeks after injection, animals were killed by CO2
inhalation for further analysis. At necroscopy, primary tumors,
stromal tissues, lungs, liver, spine were dissected and kept frozen in
liquid nitrogen for subsequent analysis. The vertebral spine was
selected for evaluation of spread to bone given the predilection of
bone metastasis to spread to this anatomic site.
Tissue slide H&E staining, immunohistochemistry and
immunoblotting
Primary tumors, lungs, spine, liver were also freshly excised and
fixed in 10% formalin overnight, immersed in 70% ethanol,
embedded in paraffin, and sectioned. The sections were followed
by H&E staining and immunohistochemistry which were de-
paraffinized with xylene and ethanol and then boiled in a pressure
cooker. After washing with Tris-Buffered-Saline (TBS) containing
0.025% Triton X-100, the sections were blocked with 10% goat
serum and incubated with primary antibody against versican G3
domain (4B6), or pERK in TBS containing 1% bovine serum
albumin (BSA) overnight. The sections were washed and labeled
with biotinylated secondary antibody, followed by avidin
conjugated horseradish peroxidase provided by the Vectastain
ABC kit (Vector, PK-4000). The slides were subsequently stained
with Mayer’s Hematoxylin for counter staining followed by slide
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grossly dissected into smaller pieces and lysated. The lysates were
sonicated and cleared by centrifugation. The supernatant was
subjected to SDS-PAGE and electroblotted onto the nitrocellu-
lose membrane. After blocked with 5% milk/TBST for 1 hour,
the membranes were incubated with monoclonal antibody against
p-ERK and monoclonal antibody 4B6 (which recognizes an
epitope at the C-terminal G3 domain) at 4uCo v e r n i g h t .A f t e r
washing with TBST (3630 minutes), the membranes were
incubated with appropriate horseradish peroxidase-conjugated
secondary antibodies in TBSTM for 1 hour. After washing as
described, the bound antibodies were visualized with an ECL
detection kit.
PCR and Real-time PCR to measure tumor burden in the
lung and bony spine tissues
Mouse lung and bony spine tissues were homogenized and the
genomic DNAs were isolated with High Pure PCR Template
Preparation kit according to the manufacturer’s instructions. In
order to estimate tumor burden, we extracted 3 samples from the
above organs of each animal, and each sample was selected from 4
different positions in the organ. Tumor burden for each individual
tissue was measured using PCR and q-RT-PCR incorporating
Taqman chemistry. Primers and probes were designed using
Primer Express, and were as follows: moVer7970F (59 cgaggc-
tagcggagctgttaccctttctccaact) and moVer10249R (59 cgagctcgag-
catgttcgccattttaaggatcag) for versican V1 isoform; CMVforward
(59 gtcatcgctattaccatggtgatgcgg) and CMVreverse (59 agctctgctta-
tatagacctcccaccg) for genome typing;; b-actinforward (59
ccggcatgtgcaaagccggcttcg) and b-actinreverse (59 ctcattgtagaa-
ggtgtggtgcc) for loading control. In regular PCR, genomic DNAs
were processed in a PCR with two appropriated primers and the
PCR products were analyzed on agarose gel and detected using
ethidium bromide staining as described previously [45].
Results
Versican expression in mouse mammary tumor cell lines
We have previously demonstrated that versican plays impor-
tant roles in mediating cell activities [46],[47]. To understand
how versican modulates signaling pathways associated with
tumor metastasis,we examined expression of versican V1isoform
(250–300 kDa) and the related molecules in different cell lines
known to possess different capacities in tumor metastasis.
Though RT-PCR showed that there was not much difference
of versican V1 expression in mRNA level among the 4 cell lines
(Fig. S1a), versican V1 protein expressed differently in the four
mouse mammary tumor cell lines. It is highly expressed in 4T1
cells, and expressed in low levels in 4T07 and 66c14 cells.
Derived from a single spontaneously arising mammary tumor
from a Balb/C mouse, these 4 mouse mammry tumor cell lines
show the same expression of versican V1 in mRNA level.
However, translational controlling and modification may play
roles in differential expression of versican V1 protein in these 4
cell lines. 4T1 cells also expressed the highest level of vimentin
and pERK. The expression of EGFR and ERK2 in the 4 cell
Figure 1. Structure of versican G3 domain and variable versican expression in mouse mammary tumor cells. (a) Immunoblotting
showed that 4T1 cells expressed highest level of versican V1 isoform, vimentin, pERK; 67NR and 66c14 cells expressed N-cadherin, while 4T07 and 4T1
cells expressed E-cadherin; In 20 ng/ml EGF medium, 4T1 cells expressed increased pEGFR and pERK. EGFR*: adding 20 ng/ml EGF for 5 min; ERK*:
adding 20 ng/ml EGF for 60 minutes. (b) Versican G3 construct (upper) was expressed in 66c14 cells, analyzed by western blot using cell lysate and
culture medium (lower). (c) Morphologically, the G3-transfected 66c14 cells appeared more elongated and spreading more evenly as compared with
the predominantly cuboid appearance of cells in the control group that tended to aggregate into clusters.
doi:10.1371/journal.pone.0013828.g001
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while 4T07 and 4T1 cells expressed E-cadherin. When treated by
20 ng/ml EGF for 5 minutes, 4T1 cells expressed the highest
level of p-EGFR. When 4T1 cells were treated by 20 ng/ml EGF
for60minutesincreasedpERKexpressionwasobserved(Fig.1a).
To investigate the effect of versican G3 on breast cancer cell
growth and metastasis, and its potential signaling pathways, we
exogenously expressed a versican G3 construct in 66c14 cells
( F i g .1 b ) .T h ee x p r e s s i o no fv e r s ican G3 in cell lysate and culture
media of 66c14 transfected cells when compared with vector
control cells is also depicted in Figure 1b. Morphologically, the
G3-transfected 66c14 cells appeared more elongated and spread
more evenly in vitro as compared with the predominant cuboid
appearance of cells that tended to aggregate into groups in the
vector control group (Fig. 1c).
Versican G3 enhances breast cancer cell adhesion
In the cell attachment assays, G3- and vector-transfected 66c14
cells, 4T07 cells, and 4T1 cells were inoculated in 6-well culture
dishes. After the cells were incubated in 2.5% FBS/DMEM
medium for 2 hours, we observed enhanced cell attachment to
culture dishes in the G3 group as compared with the vector control
(Fig. 2a). Cultured in 2.5, 5, and 10% FBS/DMEM medium for
3 hours, we observed that more G3-transfected 66c14 cells
attached to the dishes (Fig. 2b). Blockade of EGFR with AG
1478, or treating the cells with selective MEK inhibitor PD 98059
did not influence G3-induced cell attachment during the time
period evaluated (Fig. S2a, Fig. S2b).
Versican G3 activates the EGFR/ERK pathway
Immunoblotting showed that expression of G3 construct in
66c14 cells did not alter the total proteins of EGFR, ERK2, and
N-cadherin, but dramatically increased the levels of pEGFR and
pERK. The presence of G3 also up-regulated fibronectin
expression and down-regulated vimentin expression (Fig. 3a).
Cultured in 20 ng/ml EGF medium for 5-60 minutes, the G3-
transfected cells expressed increased levels of pEGFR and pERK
(Fig. 3a). Treated with 20 ng/ml EGF and different concentra-
tions of selective EGFR antagonist AG 1478 (0.2, 2.0, and
5.0 mM), the G3-activated pEGFR could be blocked with
increased dose of the inhibitory agents (Fig. 3b). Expression of
pERK was also inhibited in the G3 expressing cells cultured in the
medium with 5.0 mM AG 1478. Treated with 20 ng/ml EGF and
different concentrations of selective MEK (ERK kinase) inhibitor
PD 98059 (20, 50, and 100 mM), G3-induced expression of pERK,
but not of pEGFR, could be blocked by PD 98059 (Fig. 3c).
Versican G3 expression enhances breast cancer cell
proliferation in 66c14 cells via up-regulating the EGFR/
ERK signaling pathway
Versican G3 expression not only enhanced tumor cell adhesion,
but also enhanced cell proliferation in different culture conditions
using DMEM medium with varying concentrations of FBS. Cell
proliferation assays were performed, which indicated that the G3
construct enhanced cell growth in DMEM medium containing
2.5, 5, and 10% FBS when cultured for over 5 days (Fig. 4a). To
confirm these results, G3- and vector-transfected 66c14 cells were
inoculated in 6-well culture dishes in 10% FBS/DMEM medium.
After the cells were cultured for 12 h, the medium was changed to
contain different concentrations of FBS (2.5, 5, and 10%), and the
cells were cultured for an additional period of 3 days. Greater cell
viability was observed in the G3 group as compared with the
control group (Fig. 4b, 4c, and Fig. S3b).
Inhibitors were used to test whether versican G3 activated
breast cancer cell proliferation through EGFR-mediated signaling.
G3- and vector-transfected 66c14 cells were treated with 0.5, 2.0,
or 5.0 mM of EGFR inhibitor AG 1478 for 3 days. Analysis by
light microscopy revealed that treatment with the dose of 2.0 or
5.0 mM AG 1478 prevented G3 induced cell proliferation (Fig. 4d).
We also cultured G3- and vector-transfected 66c14 cells (2610
4)i n
10% FBS/DMEM with selective MEK inhibitor PD 98059 (20,
50, and 100 mM) for 3 days. Treatment with the dose of 50 or
100 mM PD 98059 inhibited G3-induced proliferation (Fig. 4e).
Cell growth assays performed with colorimetric proliferation assay
showed that both AG 1478 (2.0 mM) and PD 98059 (50 mM)
blocked G3-enhanced cell growth (Fig. 4f). These results suggest
that versican G3 domain promoted breast cancer cell growth
through activating EGFR/ERK pathway; blockade of EGFR or
ERK prevented G3 induced enhanced breast cancer cell
proliferation.
Versican G3 domain promotes cell cycle entry through
EGFR/ERK signaling and expression of CDK2 and
Glycogen synthase kinase-3b serine-9 phosphorylation
(GSK-3b,S 9 P )
To estimate the effect of G3 on the cell cycle, we tested
expression of cell cycle-related proteins by immunoblotting using
methods as described [48], [49]. Expression of cyclin A, cyclin B,
cyclin D, cyclin E, CDK6, and GSK-3b was similar in G3- and
vector-transfected cells, while G3 expressing cells maintained high
levels of CDK2 and GSK-3b (S9P) (Fig. 5a). Experiments with
Figure 2. Versican G3 domain enhances cell attachment. (a) G3-
and vector-transfected 66c14, 4T07, and 4T1 cells (2610
5) were
inoculated in 6-well culture dishes in DMEM containing 2.5% FBS for
2 hr. More G3-transfected cells attached on the dishes than the vector
control ones. (b) The G3- and vector-transfected 66c14 cells (2610
5)
were inoculated in 6-well culture dishes in DMEM containing 0, 2.5, 5,
and 10% FBS; more G3 transfected cells attached after 3 hours. (n=9,
*p ,0.05, ** p,0.01, analyzed with t-test).
doi:10.1371/journal.pone.0013828.g002
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in S, G2 and M stage as compared with the vector-transfected cells
(36%). Treatment with 2.0–5.0 mM AG 1478 or 50–100 mMP D
98059 inhibited the G3-induced proportional increase of cells in S,
G2 and M stages, the effect being dose-related (Fig. 5b and 5c, Fig.
S4 and S5). Immunobloting showed that 2.0–5.0 mM selective
EGFR inhibitor AG 1478 blocked G3 induced expression of
CDK2 and above 5.0 mM AG 1478 also blocked G3 enhanced
expression of GSK-3b (S9P) (Fig. 5d). While selective MEK
inhibitor PD 98059 prevented G3 promoted expression of CDK2
with concentration of 20–100 mM, and blocked G3 induced
expression of GSK-3b (S9P) at 50–100 mM (Fig. 5e).
Versican G3 enhances breast cancer cell motility through
EGFR-mediated signaling
In wound healing assays, G3-transfected cells exhibited
enhanced migratory capacity to the wounding areas, as compared
with the vector control cells (Fig. 6a, Fig. 6b, Fig. S3b). However,
G3 enhanced tumor cell migration to the wounding areas was
significantly inhibited by EGFR antagonist AG 1478 but not by
MEK inhibitor PD 98059 (Fig. 6a, Fig. 6b), suggesting that
versican G3 enhanced breast cancer cell motility through EGFR
signaling in a mechanism that did not involve the ERK
downstream pathway. Using the modified chemotactic Boyden
chamber motility assays, versican G3-transfected 66c14 cells
showed enhanced migratory capacity toward the mouse bone
stromal cells, which was also prevented by EGFR inhibitor AG
1478, but not by MEK inhibitor PD 98059 (Figs. 6c and 6d).
Versican G3 domain promotes tumor growth and
spontaneous metastasis in the orthotopic model
Balb/c mice were inoculated by transdermal injection in the
dorsal paraspinal fat pad with G3- or vector-transfected cells.
Each group had 4 mice, which were assigned to experimental
groups randomly. All the other mice were sacrificed 4 weeks after
treatment. At necroscopy, animals treated with the G3-
transfected cells produced larger tumors as compared with the
control group (p,0.05) (Figs. 7a and 7b). Balb/c mice inoculated
withG3-transfectedcells became cachectic after 4weeks (Fig. 7c).
A more progressive weight loss pattern was also observed in the
G3 group (p,0.05) (Fig. 7d). Tumor growth kinetics demon-
strated that the G3 treated tumors grew faster than that of the
control group (p,0.05) (Fig. 7b). All of the animals in the versican
G3 group (4/4) developed lung metastasis when compared to
25% (1/4) in the control group (p,0.05). To test whether
versican G3 expression enhanced EGFR/ERK signaling path-
way in vivo, paraffin sections of primary tumor, lung, and spine
were stained with H&E and immunohistochemistry stained with
anti-pERK and and anti-G3 (4B6) antibodies. The experiments
demonstrated that both versican G3 and pERK were stained at
high levels in the primary tumors arising from the G3-transfected
cells (Fig. 8a). Mice in the versican G3 group developed
metastatic lesions in lung and spine, which also expressed high
levels of pERK and 4B6 (Figs. 8b and 8c). Tumor tissues of G3-
and vector-expression cell treated mice were digested and
lysated. Immunoblotting indicated that versican G3 and p-
ERK were expressed at high levelsi nt u m o r sa r i s i n gf r o mt h eG 3 -
Figure 3. pEGFR and pERK activity is enhanced by versican G3 domain. (a) Immunoblotting showed that the G3 construct did not alter the
total EGFR and ERK proteins but dramatically increased the levels of pEGFR and pERK. G3 up-regulated expression of fibronectin and down-regulated
vimentin expression. Treated with EGF (20 ng/ml), the G3-transfected 66c14 cells expressed increased levels of pEGFR and pERK. (b) Treated with EGF
(20 ng/ml) and different concentrations of selective EGFR inhibitor AG 1478 (0.2, 2.0, and 5.0 mM) increased expression of pEGFR and pERK, which
could be blocked by the selective EGFR inhibitor AG 1478. (c) Treated with EGF (20 ng/ml) and different concentrations of selective MEK inhibitor PD
98059 (20, 50, and 100 mM), PD 98059 blocked G3-induced upregulation of pERK but not of EGFR.
doi:10.1371/journal.pone.0013828.g003
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(Figs. 8d and 8e).
Tumor burden in the bony spine was detected by PCR and real-
time quantitative PCR as described [50]. The CMV signal (CMV
sequence present in stably integrated vector in tumor cells only) was
not detected in the spine tissues of the vector control mice (0/4), but
observed inthose ofthe G3treated group (2/4)(Fig. 9a). CMV signal
washigherinthespinetissuesofG3treated animalsthanthoseofthe
vector control group (p,0.05) (Fig. 9b). Real-time PCR demon-
strated that the relative metastatic tumor burden in the spine
increased 25-fold over 4 weeks in G3 treated mice than in the vector
control group (p,0.01) (Fig. 9c). The PCR results also confirmed
that the metastatic tumor burden in the lung was much higher in the
G3 treated group than inthe vector control group (p,0.05) (Fig. 9d).
Figure 4. Expression of versican G3 enhances cell proliferation by upregulating the EGFR/ERK pathway. (a) The G3- and vector-
transfected 66c14 cells (1610
3) were inoculated in 96-well culture dishes and cultured in DMEM medium containing 2.5, 5, and 10% FBS for 5 days.
Proliferation assays performed with colorimetric proliferation assay indicated that the G3 construct enhanced cell growth. (All groups compared with
vector control cells, n=8,*p ,0.05, ** p,0.01, analyzed with t-test) (b) The G3- and vector-transfected 66c14 cells (2610
4) were inoculated in 6-well
culture dishes containing 10% FBS/DMEM and cultured for 3 days. The G3-transfected cells grew faster as compared with the control group. (c) The
G3- and vector-transfected 66c14, 4T07, and 4T1 cells (2610
4 cells) were inoculated in 6-well culture dishes with 10% FBS/DMEM and cultured for 3
days. The G3-transfected cells grew faster in these cell lines as compared with the control group. (All groups compared with vector control cells, n=6,
*p ,0.05, ** p,0.01, analyzed with t-test). (d) 2610
4 G3- and vector-transfected 66c14 cells were inoculated in 6-well culture dishes and treated with
AG 1478 (0.5, 2.0, and 5.0 mM) cultured for 3 d. Analysis by light microscopy revealed that treatment with dose of 2.0 or 5.0 mM AG 1478 prevented G3
induced cell proliferation. (e) The G3- and vector-transfected 66c14 cells were treated with PD 98059 (20, 40, and 100 mM) and cultured for 3 days.
Treatment with 40 or 100 mM PD 98059 prevented G3 induced cell proliferation. (f) Cell growth assays showed AG 1478 (2.0 mM) and PD
98059(50 mM) blocked G3 enhanced cell growth. (All groups compared with vector control cells, n=8,*p ,0.05, ** p,0.01, analyzed with t-test).
doi:10.1371/journal.pone.0013828.g004
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migration are related to its EGF-like motifs
The key functions of the EGF-like motifs of versican G3 domain
were well demonstrated by our former study [22],[23]. Here we
transiently transfected cells with G3 construct, G3 fragment
lacking the EGF-like motifs (G3DEGF), and the vector, and found
that G3DEGF expression did not show enhanced cell growth and
migration as G3 transfected cells did (Fig. 10a, 10b, 10c).
Immunoblots showed that G3DEGF expressing cells did not show
enhanced pEGFR and pERK as G3 transfected cells did (Fig. 10d).
Discussion
Interaction of versican with the extracellular matrix (ECM) and
cell surface proteins is believed to enhance structural integrity
between tumor and stromal tissues and regulates cell proliferation
and metastatic potential. Versican’s effect on proliferation may be
related to its C-terminal G3 domain [22]. In astrocytoma, versican
G3 enhances tumor growth by interactions with b1 integrin and
angiogenic factor VEGF [46]. Versican/PG-M G3 domain
appears to be important in local and systemic tumor invasiveness
of human breast cancer and may enhance connectivity between
tumor cells and surrounding stromal components, in addition to
facilitating neo-vascularization through interactions with VEGF
and fibronectin [47]. Versican G3 enhances cell proliferation in
NIH3T3 fibroblasts. This effect is mediated, in part, by the action
of versican EGF-like motifs on endogenous EGF receptors [51].
Previous studies have demonstrated that versican G3 enhances
neurite growth by enhancing the epidermal growth factor receptor
(EGFR), which is associated with activation of EGFR-mediated
signaling through G3’s EGF-like motifs [52]. In this study we
demonstrated that G3 enhances mouse mammary tumor cell
growth, migration, proliferation and metastasis through up-
regulating EGFR signaling.
Given the frequency at which abnormalities in EGFR signaling
are present in human breast cancer and observations of how these
changes influence tumor cell survival, migration, metastasis, and
angiogenesis, EGFR has been an attractive target for therapeutic
manipulation. The presence of two EGF-like domains in versican
G3 and the importance of versican as a prognostic factor in breast
cancer add to the interest in further delineating the role of EGFR
and downstream signaling in invasive breast cancer [47].
Versican G3 domain appears to be important in local and
systemic invasiveness of human breast cancer [47]. The mecha-
nism behind G3 induced tumor invasiveness was of interest in the
present study. Our study demonstrated that over-expression of
versican G3 in mammary cell lines with low basal versican
expression (ie. 66c14 cells) enhanced mammary cancer growth
Figure 5. Versican G3 domain promotes cell cycle entry through the EGFR/ERK pathway. (a) The expression of cell cycle-related proteins
was analyzed by immumoblotting probed with appropriate antibodies as indicated in the methods. b-actin expression was used as a loading control.
Expression of cyclin A, cyclin B, cyclin D, cyclin E, CDK6, and GSK-3 b was similar in G3- and vector control cells. G3 expressing cells recorded higher
levels of CDK2 and GSK-3 b (S9P) compared with vector control cells. (b) 5610
4 G3- and vector-transfected 66c14 cells were inoculated in 6 well
culture dishes and cultured in 10% FBS/DMEM without or with AG 1478 (0.5, 2.0, and 5.0 mM) for 2 days. Flow cytometry results showed that more G3
expressing cells (62%) were in S, G2 and M stages than the vector cells (36%). Treating with 2.0 mM or 5.0 mM AG 1478 prevented G3 enhanced S, G2
and M cell cycle status. (c) Similarly, culturing the cells with different concentrations of selective MEK inhibitor PD 98059 (20, 50, and 100 mM), treated
with 50 or 100 mM PD 98059 prevented G3 induced enhancement of S, G2 and M cell cycle status. (d) Immunoblotting showed that selective EGFR
inhibitor AG 1478 blocked G3 induced expression of CDK2 and GSK-3 b (S9P). (e) Immunoblotting confirmed that selective MEK inhibitor PD 98059
blocked G3 induced expression of CDK2 and GSK-3 b (S9P). (All groups compared with vector control cells, n=6,*p ,0.05, ** p,0.01, analyzed with
t-test).
doi:10.1371/journal.pone.0013828.g005
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EGFR/ERK pathway. Enhanced metastasis that included bony
sites such as the spine also appeared mediated in part through
EGFR signaling. We have demonstrated that versican G3 domain
appreciably increased breast cancer cell attachment, proliferation,
and migration in vitro, and promoted local tumor growth and
metastasis in vivo. Both selective EGFR inhibitor AG 1478 and
selective MEK inhibitor PD 98059 could block this signaling
pathway and prevent versican G3 induced effects on mammary
cancer cell proliferation. Versican G3 expression also enhanced
mammary cancer cell motility by EGFR-mediated signaling. As
selective EGFR inhibitor AG 1478 blocked G3 effects on tumor
cell migration while MEK inhibitor PD 98059 did not suggest that
ERK was the main downstream signaling component when
specifically considering effects on cell migration. Significant G3
effects on the cell cycle were also observed. G3 construct promotes
cell cycle entry by expressing CDK2 and GSK-3b (S9P). Blockade
of the EGFR/ERK pathway prevents G3 induced expression of
CDK2 and GSK-3b (S9P) and as a result blocks cell cycle entry.
Recent advances in the mechanisms of oncogenesis have
revealed a close relationship between the cell cycle and apoptosis.
The progression of a cell through the cell cycle is promoted by
cyclin dependent kinases (CDKs), which are positively regulated
by cyclins and negatively regulated by CDK inhibitors [53],[54].
In progressively growing tumors, constitutive activation of the
EGFR/ERK pathway allows for G0-G1-S-phase transition and
cell division [55]. High levels of p38 or p27 activity are believed to
be a negative growth regulator and may suppress cell proliferation
by inhibiting ERK, inducing G0-G1 arrest, triggering senescence
or apoptosis [56],[57]. Any effectors that alter the balance of p27
and CDK2, ERK and p38 may have profound consequences for
tumor growth and survival. Our study demonstrates that versican
Figure 6. Versican G3 enhances tumor cell motility through EGFR signaling. (a) The G3- and vector-transfected 66c14 cells (2610
5) were
inoculated in 6-well culture dishes and cultured for 12 h. Monolayer G3- and vector-transfected cells were wounded by a sterile pipette tip to create a
1-mm cell-free path, washed with PBS, and then cultured in 10% FBS/DMEM medium with 2 mM hydroxyurea. These samples were also treated with
or without 20 ng/ml EGF, 2.0 mM 1478PD, 50 mM PD 98059. G3-transfected cells exhibited enhanced migratory capacity, which was prevented by
EGFR inhibitor AG 1478, but not by PD 98059. (b) The distances between the wounding centre and the front of the migrating cells (vertical axis) were
measured for statistical analysis. (All groups compared with vector control cells, n=10, *p ,0.05, ** p,0.01, analyzed with t-test) (c) The chemotactic
motility assays were performed using 24-well cell culture plates and the 3.0 mm cell culture insert. The results from a representative experiment are
shown. (d) The G3-transfected 66c14 cells showed enhanced migratory capacity toward the mouse bone stromal cells that was also prevented by
EGFR inhibitor AG 1478, but not by PD 98059. The modified chemotactic Boyden chamber motility assays were performed four times and were
counted in three fields of views/membrane.
doi:10.1371/journal.pone.0013828.g006
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transfected cells grew larger tumors compared with the control group (p,0.05). (b) Tumor growth curve demonstrated that G3 treated tumor grew
faster than that of the control group (n=4,*p,0.05, **p,0.01, analyzed with t-test). (c) Balb/c mice inoculated with the G3-transfected 66c14 cells
appeared cachetic after 4 w. (d) At necroscopy, a more significant weight loss pattern was observed in the G3-treated group (n=4, *p,0.05,
**p,0.01, analyzed with t-test).
doi:10.1371/journal.pone.0013828.g007
Figure 8. Versican G3 and pERK are expressed at high levels in both primary and metastatic tumors arising from G3-transfected cell
inoculations. (a) Immunohistchemistry staining showed that both versican G3 and pERK expressed at high levels in primary tumors arising from G3
transfected cell inoculations. (b) H&E of the versican G3 expressing 66c14 cells inoculated spinal metastasis lesions, which express high levels of 4B6
and pERK in immunohistchemistry staining. (c) H&E of the G3 expressing 66c14 cells inoculated lung metastasis lesions, expressing high levels of 4B6
and pERK in immunohistochemistry staining. (d) Immunobloting showed that versican G3 and pERK were expressed at high levels in the G3-
transfected cell treated tumor. (e) Expression of versican G3 and pERK were visualized by chemi-luminescence, quantified by Alphaimager 3400 and
normalized to b-actin protein controls (n=12, **p,0.01, G3 versus vector,).
doi:10.1371/journal.pone.0013828.g008
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increasing expression of pERK, CDK2, which alters the balance
of p27 and CDK2, and ERK and p38. In addition, both selective
EGFR inhibitor AG 1478 and selective MEK inhibitor PD 98059
can block expression of pERK and CDK2, and prevent versican
G3 enhanced cell cycle entry and cell growth.
It is possible that signaling pathways associated with cell survival
could also make a contribution to tumor invasion through a direct
effect of versican on tumor cells. Glycogen synthase kinase-3b
(GSK-3b), a serine/threonine protein kinase involved in glycogen
metabolism and the EGFR-mediated signaling pathway, appears
to play an important role in embryonic development and
tumorigenesis [58],[59]. Over-expression of GSK-3b can induce
apoptosis in tumor cells, whereas inactivation of GSK-3b through
phosphorylation of the Serine 9 residue can reduce apoptosis and
enhance cell survival [58],[60]. In the current study, we found that
the activity of GSK-3 b (S9P) increases in versican G3 expressing
cells, which is required for tumor cell survival and anti-apoptosis.
Regulation of GSK-3b activity through both serine and tyrosine
phosphoylation is a critical determinant of cell death or survival
[61],[62]. Factors that promote cell survival, such as growth
factors, activate EGFR/Akt which in turn phosphorylates GSK-3b
at Serine 9, leading to inactivation of its kinase activity [62].
Selective EGFR AG inhibitor 1478 and ERK inhibitor PD 98059
prevent G3 induced phosphorylation of GSK-3b at Ser-9, leading
to activation of GSK-3b activity, which is related to cell apoptosis.
Consistent with studies in vitro, in vivo experiments demon-
strated that versican G3 enhanced the spontaneous metastasis of
tumors from the mammary gland to distant organs including bone
and contributed towards a more aggressive phenotype. G3’s effect
on in vivo local tumor growth was associated with changes in
EGFR signaling, and p-ERK expression levels were observed to be
more than two-fold greater in primary tumors of G3 treated mice
as compared with those of the vector control group. To our
knowledge, our study provides the first direct in vivo evidence that
tumor specific expression of versican G3 domain, EGFR and
pERK contributes to the spontaneous metastasis of mammary
tumors from the fat pad to systemic distant organs. A more
aggressive weight loss and lung metastasis pattern was observed in
the G3 treated group when compared to the control group. Most
importantly, we report in the present article that expression of the
versican G3 domain in a mammary tumor cell line (66c14) that
does not normally metastasize to bone is sufficient to promote their
spontaneous metastasis to this tissue site. Whether this is
Figure 9. Versican G3 domain promotes breast cancer cell metastasis in vivo. (a) The CMV signal was not detected in the spine tissues of
the vector control mice, but could be detected in the G3-treated group. (b) Expression of CMV signal was visualized and quantified by Alphaimager
3400 and normalized to b-actin signal controls. Each point represents one sample, but not all points are distinguishable. The average normalized CMV
signal for each group is shown with a line (n=12, *p,0.05, analyzed with t-test). (c) The tumor burden in spine was measured by real-time
quantitative PCR as described in Materials and Methods. The metastatic tumor burden of spine increased 25-fold in the G3-treated mice than in
vector control group (n=12, *p,0.05, analyzed with t-test). (d) The metastatic tumor tissues in mouse lungs were detected by PCR as described in
the study methods.
doi:10.1371/journal.pone.0013828.g009
Versican Promoted EGFR Signals
PLoS ONE | www.plosone.org 11 November 2010 | Volume 5 | Issue 11 | e13828predominantly an effect of G3 or of tumorgenicity in the time-
course of metastatic spread warrants ongoing study although in
vitro chemotactic motility assays did support enhanced G3
induced cell migration towards bone. Of interest would include
evaluating factors (eg. alphavbeta3 integrin) that may promote
chemotactic/haptotactic migration towards bone [63]. Versican
expression may be important during the process of tumor bony
invasion and subsequent remodeling of bone that leads to
osteolysis with a resultant loss in mature organized bony micro-
architecture [47]. Previous research has shown that the interaction
of beta1-integrin with the C-terminal domain of PG-M/versican
activates focal adhesion kinase enhancing integrin expression and
promoting cell adhesion [15]. Versican G3 has been shown to
interact with beta1-integrin in other cancer cell types [63],[64].
The increasing knowledge of several beta3 integrin-expressing cell
populations, including osteolasts in breast cancer tumor progres-
sion, suggests that versican-integrin mediated interactions may be
important in bony metastatic spread [63],[64].
To summarize, we have found that expression of versican G3
promoted breast cancer cell growth and metastasis through up-
regulating active EGFR expression and activation of the EGFR-
mediated pathway. Versican G3 domain appreciably increased
breast cancer cell attachment, proliferation, and migration in vitro.
G3 promoted tumor growth and systemic metastasis in vivo.
Blockade of EGFR with AG1478 or blockade or ERK with PD
98059 inhibited versican G3 effects on cell proliferation. Blockade
of EGFR also inhibited G3 effects on tumor cell chemotactic
migration to bone stromal cells; while inhibition of EGFR and
ERK did not significantly influence G3’s effect on cell attachment.
Although we do not know whether the high expression of EGFR
Figure 10. Versican G3 domain modulates breast cancer cell growth and migration via its epidermal growth factor-like motifs. (a)
Vector-, G3- and G3DEGF- transiently transfected 66c14 cells and 4T07 (2610
4) were inoculated in 6-well culture dishes containing 10% FBS/DMEM
and cultured for 3 days. Cells were counted under light microscopy. (b) Vector-, G3- and G3DEGF- transiently transfected 66c14 cells (2610
5) were
inoculated and cultured in 6-well culture dishes containing 10% FBS/DMEM for 12 h. all the samples were wounded by a sterile pipette tip to create a
1-mm cell-free path, washed with PBS, cultured in 10% FBS/DMEM medium with 2 mM hydroxyurea for 3 d. (c) The distances between the wounding
centre and the front of the migrating cells (vertical axis) were measured for statistical analysis. (All groups compared with vector control cells, n=10,
*p ,0.05, ** p,0.01, analyzed with t-test). (d) Cell lysates of vector-, G3- and G3DEGF- transiently transfected 66c14 cells were prepared and
subjected to immunoblotting with antibodies to 4B6, pEGFR, EGFR, pERK and ERK2.
doi:10.1371/journal.pone.0013828.g010
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other molecular determinants, understanding the signaling
cascade is important towards the mechanisms of action in factors
that influence tumor invasiveness.
Supporting Information
Figure S1 Expression of Versican V1 isoform in of the 4 mouse
breast cancer cell lines in RT-PCR.
Found at: doi:10.1371/journal.pone.0013828.s001 (0.07 MB
PDF)
Figure S2 Blockade of EGFR with AG 1478, or treating the cells
with selective MEK inhibitor PD 98059 did not influence G3-
induced cell attachment during the time period evaluated. (a) G3-
and vector-transfected 66c14 cells (26105) were inoculated in 6-
well culture dishes in DMEM containing 2.5% FBS without or
with AG 1478 (0.5, 2.0, and 5.0 mM) for 2 hr. (b) The G3- and
vector-transfected 66c14 cells (26105) were inoculated in 6-well
culture dishes in DMEM containing 2.5% FBS with selective
MEK inhibitor PD 98059 (20, 50, and 100 mM) for 2 hr. (All
groups compared with G3 transfected 66c14 cells cultured in
DMEM containing 2.5% FBS, n=9, * p,0.05, ** p,0.01,
analyzed with t-test).
Found at: doi:10.1371/journal.pone.0013828.s002 (0.08 MB
PDF)
Figure S3 Expression of G3 enhances cell proliferation and
migration in human breast cancer cell lines. (a) 26104 G3- and
vector-transfected MT-1, MDA-MB-231, and MDA-MB-468 cells
were inoculated in 6-well culture dishes with 10% FBS/DMEM
and cultured for 3 days. More G3-transfected cells grew in these
cell lines as compared with the control group. (All groups
compared with vector control cells, n=6, * p,0.05, ** p,0.01,
analyzed with t-test). (b) The G3- and vector-transfected MDA-
MB-468 cells (26105) were inoculated in 6-well culture dishes and
cultured for 12 h. Monolayer G3- and vector-transfected cells
were wounded by a sterile pipette tip to create a 1-mm cell-free
path, washed with PBS, and then cultured in 10% FBS/DMEM
medium for 3 days. Pictures were taken under the light
microscopy. The distances between the wounding centre and the
front of the migrating cells (vertical axis) were measured for
statistical analysis. (All groups compared with vector control cells,
n=10, * p,0.05, ** p,0.01, analyzed with t-test).
Found at: doi:10.1371/journal.pone.0013828.s003 (0.08 MB
PDF)
Figure S4 Typical flow cytometry plots showing that versican
G3 domain promotes cell cycle entry, while AG 1478 prevented
G3 enhanced S, G2 and M cell cycle status.
Found at: doi:10.1371/journal.pone.0013828.s004 (0.48 MB
PDF)
Figure S5 Typical flow cytometry plots showing that versican
G3 domain promotes cell cycle entry, while PD 98059 prevented
G3 enhanced S, G2 and M cell cycle status.
Found at: doi:10.1371/journal.pone.0013828.s005 (0.49 MB
PDF)
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